NEW YORK – Mythic Therapeutics on Tuesday said that the first non-small cell lung cancer patient has received its cMET-targeting antibody-drug conjugate MYTX-011 in a Phase I trial.
Waltham, Massachusetts-based Mythic is evaluating MYTX-011 as a treatment for locally advanced, recurrent, or metastatic NSCLC. In the first part of the Phase I KisMET-01 trial, Mythic will evaluate the antibody-drug conjugate's safety and tolerability in an all-comer population of NSCLC patients. In the second part, Mythic will evaluate overall response rates in NSCLC patients according to cMET expression, MET amplification, or the presence of MET exon 14 skipping mutations.
The first patient in the trial was treated at the Sarah Cannon Research Institute at Tennessee Oncology. Researchers expect to enroll 150 patients in the trial.
Mythic ADCs use a proprietary technology, dubbed FateControl, which it claims can enhance ADC uptake in targeted tissues and improve therapeutic efficacy across a broad population of patients with various molecular targets.
"Today's announcement of our first subject dosed represents a significant step towards increasing the number of lung cancer patients eligible for treatment using ADCs, including those whose cancers express moderate cMET levels," Mythic CSO and Cofounder Brian Fiske said in a statement. "At Mythic, we are focused on our vision of unlocking the full potential of MYTX-011 as well as our broader pipeline of ADCs incorporating FateControl technology, which represents a fundamentally new paradigm for ADC therapies."